|
公司基本資料信息
|
MIM1 is a selective small molecule inhibitor of Mcl-1(IC50= 4.8 uM) that overcomes Mcl-1-dependent leukemia cell survival.
IC50 value: 4.8 uM
Target: Mcl-1
MIM1 effectively competed with FITC-MCL-1 SAHBA and FITC-BID BH3 for MCL-1ΔNΔC binding with respective IC50s of 4.7 and 4.8 μM, the compound showed no capacity to displace FITC-BID BH3 from BCL-XLΔC (IC50>50 μM), mirroring the selectivity of MCL-1 SAHBD.
Although MCL-1 SAHBD was a 30 to 60-fold more potent competitor for MCL-1ΔNΔC binding than MIM1, the MCL-1 selective small molecule is one-seventh the size of the stapled peptide and exhibits an IC50 for its target (4.8 μM) that is only 7.5-fold less than that of chemically-optimized ABT-737 for BCL-XLΔC (0.63 μM) upon competition with FITC-BID BH3.
MCE 對每批產(chǎn)品都進(jìn)行嚴(yán)格的LCMS和NMR檢驗,其產(chǎn)品已被全球近萬名客戶廣泛使用并發(fā)表大量文章、專利;
MCE 定期增加各領(lǐng)域熱門抑制劑、激動劑,不斷擴(kuò)增已有化合物庫,以滿足最新的科研需求;
數(shù)千種產(chǎn)品在上海有充足備貨,24-48小時內(nèi)送達(dá)客戶;
大量產(chǎn)品提供免費試用裝;
已為全球多個知名企業(yè)、院校構(gòu)建各種定制型化合物庫。
產(chǎn)品鏈接:
http://www.medchemexpress.cn/mim1.html